Swissmedic laboratory publishes test method for nitrosamines in sartans


Test method for active substances and finished medicinal products

Following the recall of sartan-containing medicinal products due to contamination with nitrosamines, Swissmedic's own OMCL (official medicines control laboratory) has been testing other sartans with a similar chemical structure. The Swissmedic laboratory has developed a sensitive test method for these substances. This method can be used to establish whether the content of N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA) is above or below the safety limit.

The analytical procedure for detecting the nitrosamines NDMA and NDEA is complex, and developing suitable test methods is therefore time-consuming. To enable sensitive tests to be introduced swiftly, Swissmedic has decided to publish its analytical method.

Swissmedic will require the Swiss authorisation holders of all sartan-containing medicinal products with the active substances candesartan, irbesartan, losartan, olmesartan and valsartan to perform systematic tests for the nitrosamines NDMA and NDEA. In future, all deliveries of the above-mentioned active substances received by these companies will have to be analysed.

The publication of the test method (limit test) is intended to enable the companies to establish a sufficiently sensitive and specific test procedure and thus help to avoid shortages of supply.

Related documents

Further links



Swissmedic analysis method for controlling the limits of NDMA and NDEA nitrosamines in various API's

Last modification 14.12.2018

Top of page